BiotechTube

AK135

Phase 1Recruiting
0 watching 0 views this weekπŸ’€ Quiet
32
Hype Score

Development Stage

βœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chemotherapy-induced Peripheral Neuropathy (CIPN)

Conditions

Chemotherapy-induced Peripheral Neuropathy (CIPN)

Trial Timeline

Feb 28, 2025 β†’ Dec 31, 2027

NCT ID
NCT06860789

About AK135

AK135 is a phase 1 stage product being developed by Akeso for Chemotherapy-induced Peripheral Neuropathy (CIPN). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06860789. Target conditions include Chemotherapy-induced Peripheral Neuropathy (CIPN).

Hype Score Breakdown

Clinical
10
Activity
5
Company
9
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06860789Phase 1Recruiting

Competing Products

20 competing products in Chemotherapy-induced Peripheral Neuropathy (CIPN)

See all competitors
ProductCompanyStageHype Score
SON-080Sonnet BioTherapeuticsPhase 1/2
36
GranisetronKyowa KirinPhase 3
77
ONO-7746Ono PharmaceuticalPhase 1
33
ONO-2910 + PlaceboOno PharmaceuticalPhase 2
52
PROCRIT 40,000 IU QW + PlaceboJohnson & JohnsonPhase 2
52
Hetrombopag Olamine + Hetrombopag Olamine οΌ›Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
77
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 2
52
Hetrombopag + Hetrombopag plus Placebo + PlaceboJiangsu Hengrui MedicinePhase 3
77
Hetrombopag + Matching placeboJiangsu Hengrui MedicinePhase 3
77
Hetrombopag + PlaceboJiangsu Hengrui MedicinePhase 3
77
Fosaprepitant dimeglumine + Fosaprepitant Placebo + Dexamethasone + Ondansetron + Dexamethasone Placebo + Ondansetron Placebo + Rescue TherapyMerckPhase 3
77
FosaprepitantMerckPhase 2
52
Fosaprepitant + Placebo for fosaprepitant + Ondansetron + Dexamethasone + 5-HT3 antagonistMerckPhase 3
77
Fosaprepitant + Dexamethasone + 5HT3MerckPhase 2
52
aprepitant + Comparator: Placebo to aprepitant + dexamethasone + granisetron + dexamethasoneMerckPhase 3
77
aprepitant + Comparator: ondansetron + Comparator: dexamethasone + Comparator: fosaprepitant dimeglumine + Comparator; Placebo (unspecified) + Comparator; Placebo (unspecified)MerckPhase 3
77
EMENDMerckPre-clinical
23
Fosaprepitant Dimeglumine + 5-HT3 antagonist + DexamethasoneMerckApproved
85
ondansetron clinical trial formulation + ondansetron marketed formulationMerckPhase 1
33
Aprepitant + Palonosetron + DexamethasoneMerckPhase 2
52

Other Products from Akeso

AK104(SC) + AK104(IV) + Capecitabine + Oxaliplatin injectionPhase 3
76
AK111 + AK111 + PlaceboPhase 3
76
AK104 + LenvatinibPhase 3
76
Cadonilimab (AK104) + Oxaliplatin + Capecitabine + 5- Fluorouracil + Calcium FolinatePhase 3
76
AK102 + AK102 + Placebo + PlaceboPhase 3
76